Experimental Drug Improved Myasthenia Gravis Symptoms
A new once-weekly injection helped adults with muscle weakness regain daily function in a clinical trial.
Updated on Oct. 14, 2026 in Stroke
Live Poll
Should regulatory authorities prioritize the approval of at-home administration for new rare disease treatments?
The PREVAIL phase 3 clinical trial evaluated the experimental subcutaneous injection gefurulimab for adults with generalized myasthenia gravis. Published results from 2026 indicate that the treatment improved muscle strength and daily activity performance compared to a placebo.
Why it matters
Myasthenia gravis is a chronic autoimmune disease that lacks a cure, making the development of new, effective treatment options essential for managing patient quality of life. The study highlights the necessity of international collaboration to generate robust clinical data for rare diseases.
This phase 3 trial enrolled 260 patients across 113 centers in 20 countries to test gefurulimab. After six months, 65.5% of treated patients achieved the daily activity improvement criterion, compared to 52.2% in the placebo group.
The players
Bellvitge Universitary Hospital
A major medical facility that coordinated the Spanish participation in the international clinical trial.
The details
Gefurulimab is designed as a once-weekly subcutaneous injection that patients or caregivers can administer at home. In the trial, improvements in daily activities were observed as early as the first week of treatment. Clinical evidence of muscle strength gains became measurable by the fourth week of the study.
Timeline
Week 1: Improvements in daily activities were observed.
Week 4: Clinical improvements in muscle strength became evident.
6 months: Study period concluded for measurement of improvement criteria.
Health Landscape
The PREVAIL phase 3 clinical trial represents a significant effort to establish new standards of care for patients with generalized myasthenia gravis. It follows the historical arc of utilizing international multi-center studies to secure evidence for rare disease treatments.
Patients living with myasthenia gravis should monitor changes in their muscle strength and daily function when starting new treatment protocols. It is worth discussing with your doctor whether emerging, once-weekly injection options are appropriate for your specific care plan.
The takeaway
The study demonstrates that gefurulimab can meaningfully improve daily function for those managing myasthenia gravis. If you are tracking your symptoms, consider keeping a record of your physical strength and activity levels to share with your physician during your next consultation.
Further reading
For more information on managing neuromuscular conditions, visit our Stroke section.
More information
View the complete JAMA Neurology study report for full trial methodology and data.
Source note: This article includes information reported by Biotech-spain.
Live Poll
Should regulatory authorities prioritize the approval of at-home administration for new rare disease treatments?
